Verapamil kinetics during maintenance hemodialysis.

Area of Science:

• Pharmacokinetics
• Nephrology
• Internal Medicine

Background:

• Verapamil is a commonly prescribed calcium channel blocker.
• End-stage renal disease (ESRD) can alter drug pharmacokinetics.
• Understanding verapamil's behavior in ESRD patients is crucial for safe and effective treatment.

Observation:

• This study evaluated verapamil pharmacokinetics in a patient undergoing maintenance hemodialysis.
• Drug levels and elimination half-lives were monitored during chronic oral therapy.
• Hemodialysis efficacy in removing verapamil and its metabolite was assessed.

Findings:

• The elimination half-life of verapamil was 3.8 hours, shorter than in patients with normal renal function.
• The elimination half-life of its major metabolite, norverapamil, was 15.2 hours, similar to normal renal function.
• Hemodialysis did not significantly impact verapamil's half-life, and neither verapamil nor norverapamil were detected in the dialysate.

Implications:

• Verapamil pharmacokinetics are altered in patients with end-stage renal disease.
• Standard hemodialysis is not effective in clearing verapamil or its metabolite.
• Dosage adjustments or alternative antihypertensive agents may be necessary for ESRD patients on verapamil.